Swedish Orphan Biovitrum publ AB (SOBIV.ST) Quote| Reuters.com
Edition:
United States

Swedish Orphan Biovitrum publ AB (SOBIV.ST)

SOBIV.ST on Stockholm Stock Exchange

103.70SEK
1 Jul 2016
Change (% chg)

0.90kr (+0.88%)
Prev Close
102.80kr
Open
104.00kr
Day's High
104.00kr
Day's Low
100.50kr
Volume
1,541,738
Avg. Vol
1,646,852
52-wk High
140.30kr
52-wk Low
92.60kr

SOBIV.ST

Chart for SOBIV.ST

About

Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers... (more)

Overall

Beta: 1.36
Market Cap(Mil.): kr27,796.07
Shares Outstanding(Mil.): 270.39
Dividend: --
Yield (%): --

Financials

  SOBIV.ST Industry Sector
P/E (TTM): 93.90 35.27 36.15
EPS (TTM): 1.09 -- --
ROI: 4.52 15.09 14.31
ROE: 6.11 16.14 15.51

BRIEF-Sobi says Alprolix wins regulatory approval in EU

* Says Alprolix (rfixfc) approved in the EU for the treatment of Haemophilia B

May 13 2016

NORDIC STOCKS - Factors to watch on May 4

The following stocks may be affected by newspaper reports and other factors on Wednesday:

May 04 2016

BRIEF-SOBI: Outgoing chairman sells 8 million shares

* Outgoing chairman Bo Jesper Hansen has sold 8 million shares

May 04 2016

BRIEF-Sobi extends manufacturing agreements with Pfizer

* The agreement has been extended until Dec 31, 2023 Source text for Eikon: Further company coverage:

Apr 29 2016

BRIEF-Sobi CEO on Biogen assets: "not a time to bet the company"

* CEO, asked about interest in Biogen's hemophilia assets, says "this is not a time to bet the company on something that is at the outer limits of our capacity"

Apr 27 2016

BRIEF-Sobi CEO says currently not looking to sell the company

April 27 Sobi CEO in news wire call after Q1 report:

Apr 27 2016

BRIEF-Sobi Q1 EBITA beats forecast, repeats 2016 outlook

* Reuters poll: Q1 EBITA was seen at sek 463 million, revenues at 1,336 million Source text for Eikon: Further company coverage:

Apr 27 2016

BRIEF-Sobi says signs licensing agreement with Affibody for IL-1

* Says exercised its option to sign a licensing agreement with Swedish biotech company Affibody AB for the development of novel treatments for inflammatory diseases where interleukin-1 (IL-1) is involved Source text for Eikon: Further company coverage: (Stockholm Newsroom)

Apr 22 2016

BRIEF-Sobi: Raises 2016 sales, profit guidance

* updating its outlook for 2016 after positive opinion for Alprolix received from the Committee for Medicinal Products for Human Use (CHMP) on Friday 26 February

Feb 29 2016

BRIEF-Sobi: CEO says company not for sale, don't expect dividends near term

* Says company not for sale, can't refuse to discuss should a bidder offer very high premium, but that's not on our wish list Further company coverage:

Feb 26 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : MacroRisk Analytics/EconomicInvestor
$25.00
Provider : Sadif Analytics Prime
$25.00
Provider : Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.